The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease

American Journal of Lifestyle Medicine

Volumn 1, Issue 1, 2007, Pages 10-19

  Rippe, James M ^a,b,c,d   Angelopoulos, Theodore J ^d   Zukley, Linda ^e  

^a Rippe Lifestyle Institute   (United Kingdom)

^b Florida Hospital Institute for Lifestyle Medicine Celebration   (United Kingdom)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA   (United States)

^e Florida Hospital Celebration Health   (United Kingdom)

Author keywords

Coronary heart disease (CHD); diabetes; dyslipidemia; hypertension; obesity; physical activity; risk factors

Indexed keywords

EID: 84990316900     PISSN: 15598276     EISSN: None     Source Type: Journal    
DOI: 10.1177/1559827606292859     Document Type: Review

References (114)

1. American Heart Association. Heart Disease and Stroke Statistics–2006: An Update. Dallas, Tex: American Heart Association; 2006.
2. Howson CP, Reddy SK, Rayan TJ, Bale Jr. Control of Cardiovascular Diseases in Developing Countries. Washington, DC: National Academy Press; 1998.
3. Rippe JM, O'Brien D: The rationale for intervention to reduce the risk of coronary artery disease. In: Rippe JM, ed. Lifestyle Medicine. London: Blackwell Science; 1999.
4. National Institutes of Health, National Heart, Lung and Blood Institute. Fact Book Fiscal Year 2003. Bethesda, Md: National Institutes of Health; 2004.
5. American Heart Association. Heart Disease and Stroke Statistics–2004 Update. Dallas, Tex: American Heart Association; 2003.
6. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993; 269: 3002-3002.
7. Eckel R. Obesity and heart disease: a statement for the healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997; 96: 3248-3250.
8. Surgeon General's Report on Physical Activity and Health. Washington, DC: US Department of Health and Human Services, Centers for Disease Control; 1999.
9. US Department of Health and Human Services. Women and Smoking: A Report of the Surgeon General. Rockville, Md: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001.
10. Cigarette smoking among adults–United States, 2000. MMWR Morb Mortal Wkly Rep. 2002; 51: 642-642.
11. Eyre H, Kahn R, Robertson R. ACS/ADA/AHA scientific statement: preventing cancer, cardiovascular disease and diabetes. Circulation. 2004; 109: 3244-3255.
12. Wilson PWF, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837-1847.
13. Kannel WB. Cigarette smoking and coronary heart disease. Ann Intern Med. 1964; 60: 1103-1106.
14. Wilson PW, Garrison RJ, Castell WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 1985; 313: 1038-1043.
15. Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham Study. J Card Rehabil. 1984; 4: 267-277.
16. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987; 113: 1006-1010.
17. Shea S, Cook EF, Kannel WB, Goldman L. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study. Circulation. 1985; 71: 22-30.
18. Kannel WB, Danneberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J. 1985; 109: 581-585.
19. Harris T, Cook EF, Kannel W, Schatzkin A, Goldman L. Blood pressure experience and risk of cardiovascular disease in the elderly. Hypertension. 1985; 7: 118-124.
20. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986; 80: 23-32.
21. Kanell WB, Castell WP, Gordon T, McNamara PM. Serum cholesterol, lipo-proteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1971; 74: 1-12.
22. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980; 46: 649-654.
23. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983; 67: 730-734.
24. McNamara JR, Cohn JS, Wilson PW, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 1990; 36: 36-42.
25. Gordon DL, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989; 79: 8-15.
26. Garcia MJ, McNamara P, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population 16-year follow-up study. Diabetes. 1974; 23: 105-111.
27. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979; 59: 8-13.
28. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA. 1988; 260: 3456-3460.
29. Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990; 120: 672-676.
30. Fletcher G, Blair S, Blumenthal J, et al. AHA medical/scientific statement. Statement of exercise. Benefits and recommendations for physical activity programs for all Americans. Circulation. 1992; 86: 340-344.
31. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professional. Circulation. 1991; 83: 356-356.
32. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988; 62: 1109-1112.
33. Wilson P. Clustering of risk factors, obesity, and syndrome X. Nutr Clin Care. 1998; 1(Suppl): 44-50.
34. Farmer JA, Gotto AM. Dyslipidemia and Other Risk Factors for Coronary Artery Disease in Braunwald: Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: W. B. Saunders; 1997.
35. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA task force on risk reduction. Circulation. 1998; 97: 1876-1887.
36. Stamler J. Epidemiology, established major risk factors and the primary prevention of coronary heart disease. In: Chatterjee K, Cheitlin MP, Karlines J, et al, eds. Cardiology: An Illustrated Text Reference. Vol. 2. Philadelphia: J. B. Lippincott; 1991: 1-1.
37. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993; 308: 363-366.
38. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: data from the BUPA study. Br Med J. 1994; 308: 363-366.
39. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? Br Med J. 1994; 308: 367-373.
40. Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. Ann Int Med. 1985; 103: 1006-1009.
41. Stamler J, Wentworth D, Naton JD. For the MRFIT Research Group: is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256; 2823-2823.
42. Rimm EB, Stampler MJ, Giovannucci B, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995; 141: 1117-1127.
43. Manson JE, Willett WC, Stampler JM, et al. Body weight and mortality among women. N Engl J Med. 1995; 141: 1117-1127.
44. Annual smoking attributable mortality, years of potential life lost, and economic costs–United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2000; 51: 300-300.
45. Smoking-Related Deaths and Financial Costs: Estimates for 1990. Rev. ed. Washington, DC: Office of Technology Assessment; 1993.
46. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens. 1990; 8: S3-S3.
47. Negri E, Franzosi MG, LaVecchia C, et al. Tar yield of cigarettes and risk of acute myocardial infarction. BMJ. 1993; 306: 1567-1567.
48. Bolinder G, Alfredsson L, Englund A, deFaire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health. 1994; 84: 399-399.
49. Sigurdsson G Jr, Gudnason V, Sigurdsson G, Humphries SE. Interaction between a polymorphism of the apo A-I promoter region and smoking determines plasma levels of HDL and apo A-I. Arterioscler Thromb. 1992; 12: 1017-1017.
50. Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factors modifications. Circulation. 1991; 83: 1194-1194.
51. Dobvson AJ, Alexander HM, Heller RF, Lloyd DM. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol. 1991; 44: 1247-1247.
52. Physician and other health-care professional counseling of smokers to quit-United States, 1991. MMWR Morb Mortal Wkly Rep. 1993; 42: 854-854.
53. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251: 351-351.
54. Huttunen JK, Manninen V, Manttair M, et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med. 1991; 23: 155-155.
55. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial in healthy men. Lancet. 1991; 2: 1303-1303.
56. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J. 1978; 40: 1069-1069.
57. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with provastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-1301.
58. Brensike JF, Levy RI, Kelsy SF, et al. Effects of therapy with cholestryamine on progression of coronary ateriosclerosis: results of NHLBI Type II Coronary Intervention Study. Circulation. 1984; 69: 313-313.
59. Brown G, Albers J, Fisher L, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apoliporotein B. New Engl J Med. 1990; 323: 1289-1289.
60. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St. Thomas Atherosclerosis Regress Study (STARS). Lancet. 1992; 339: 563-563.
61. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholeterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990; 323: 946-946.
62. Wiviott SD, deLemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006; 113: 1406-1414.
63. Gordon T, Castelli WP, Hjortland MC, et al. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977; 62: 707-707.
64. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991; 11: 2-2.
65. Chobanian AV, Bakris G, Black H, et al, and the National Health High Blood Pressure Education Program Coordinate Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003; 289: 2560-2571.
66. Kannel WB. Fifty years of Framingham Study contributions to understanding hyper-tension. J Hum Hypertens. 2000; 14: 83-90.
67. Staessen JA, Gasowski J, Wang JG, et al. Risks of treated and untreated and treated metabolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355: 865-872.
68. O'Donnell CJ, Ridker PM, Glynn RJ, et al. Hypertension and borderline isolate systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation. 1997; 95: 1132-1132.
69. Working Group on Management of Patients With Hypertension and High Blood Cholesterol. National education programs working group report on the management of hypertension and high blood cholesterol. Ann Intern Med. 1991; 114: 224-237.
70. Howard BV, Rodriguez BL, Bennett PH, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group I: Epidemiology. Circulation. 2002; 105: e132-e132.
71. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998; 21: 1138-1138.
72. National Center for Statistics. Healthy People 2010. Hyattsville, Md: National Center for Statistics; 2005.
73. Powell K, Thompson P, Caspersen C, Kendrick J. Physical activity and the incidence of coronary heart disease. Ann Rev Public Health. 1987; 8: 253-287.
74. Goldfine H, Ward A, Taylor P, Carlucci D, Rippe JM. Exercising to health: what's really in it for your patients? Part I: The health benefits of exercise. Phys Sports Med. 1991; 19: 81-81.
75. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults: 1999-2000. JAMA. 2002; 288: 1723-1727.
76. Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. World Health Organization Tech Rep Ser. 1995; 854: 1-452.
77. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993; 4: 452-459.
78. Despres JP. Dyslipidaemia and obesity. Bailliere Clinic Endo Metab. 1994; 8: 629-660.
79. Willett W, Manson J, Stampfer M, et al. Weight, weight change, and coronary heart disease in women. JAMA. 1995; 273: 461-465.
80. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994; 17: 961-969.
81. American Heart Association. Heart and Stroke Facts. 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1994.
82. Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol. 1991; 67: 993-993.
83. Mosca L, Appel L, Benjamin E, et al. Evidenced-based guidelines for cardiovascular disease prevention in women. Circulation. 2004; 109: 672-693.
84. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year old follow-up of the Framingham population. Am Heart J. 1994; 15: 1571-1571.
85. Ford ES, Giles WH, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-356.
86. Libby P, Ridker PM, Maser A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1125-1125.
87. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002; 347: 5-5.
88. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA. 2002; 288: 980-980.
89. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002; 105: 2595-2595.
90. Ridker PM, Cushman M, Stampher MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-973.
91. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-836.
92. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of the intercellular adhesion molecule 1 and risks of future myocardial infarction in inherently healthy men. Lancet. 1998; 351: 88-88.
93. Ridker P, Libby P. Risk factors for atherothrombotic disease. In: Zipes D, Libby P, Bonow R, Braunwald E., eds. Braunwald's Heart Disease (7th edition). Philadelphia: Elsevier Saunders; 2005.
94. Welch GN, Loscalso J. Homocysteine and atherothrombosis. N Engl J Med. 1998; 338: 1042-1050.
95. Spence JD, Howard VJ, Chambless LE, et al. Vitamin intervention for stroke prevention (VISP) trial: rationale and design. Neuroepidemiology. 2001; 20: 16-16.
96. Ridker PM, Manson JE, Buring JE, et al. Homocyst(e)ine and risk of cardiovascular disease among postmenopausal women. JAMA. 1998; 281: 1817-1817.
97. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Homocystine Lowering Trialists' Collaboration. BMJ. 1998; 316: 894-894.
98. MacMahon M, Kirkpatrick C, Cummings CE, et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocystein (SEARCH). Nutr Metab Cardiovasc Dis. 2000; 10: 195-195.
99. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein (a) further increases the risks of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001; 37: 434-434.
100. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999; 100: 1154-1154.
101. Luc G, Bard JM, Arveiller D, et al. Lipoprotein (a) as a predictor of coronary heart disease. The PRIME Study. Arthrosclerosis. 2002; 163: 377-377.
102. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein as a predictor of the risk of ischemic heart disease in men. Prospective trial from the Quebec Cardiovascular Study. Circulation. 1977; 95: 69-69.
103. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoproteins subclass levels and low density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of arthrosclerosis in the coronary arteries (PLAC I) trial. Am J Card. 2002; 90: 89-89.
104. Pohorecky LA. Interaction of alcohol and stress at the cardiovascular level. Alcohol. 1990; 7: 537-546.
105. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high density lipoprotein and its subfractions and decreased risk of myocardial infarction. N Engl J Med. 1993; 329: 1829-1834.
106. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary heart disease in women. N Engl J Med. 1993; 328: 1444-1444.
107. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328: 1450-1450.
108. Alpha-Tocopheral, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotenes on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994; 330: 1029-1029.
109. Lachar BL. Coronary-prone behavior: type A behavior revisited. Tex Heart Inst J. 1993; 20: 143-143.
110. Littman AB. Review of psychosomatic aspects of cardiovascular disease. Psychotera Psychosom. 1993; 60: 148-148.
111. Keelan PC, Bielak LF, Ashai K, et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001; 104: 412-412.
112. Achenbach S, Ropers D, Pohle K, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002; 106: 1077-1077.
113. Hodis, HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness predicting clinical coronary events. Ann Intern Med. 1998; 128: 262-269.
114. O'Leary DH, Plak JF, Kronman RA, Manolio TA, Burke GL, Wolfson SK. Carotid artery intima and media thickness as a risk for myocardial infarction and stroke in older adults. The Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 14-22.